AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04778956
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Trial: NCT05292131
Drug: bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
Trial: NCT04609514
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
Trial: NCT00000989
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000989
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000989
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05618223
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg once daily in addition to standard therapy
Trial: NCT05049525
Drug: Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
Trial: NCT05049525
Drug: Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
Trial: NCT06206044
Drug: Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive standard intrathecal medications for urgent and scheduled cesarean delivery at the study site. All study subjects will receive bupivacaine, fentanyl, and morphine.
Trial: NCT05457842
Drug: pudexacianinium chloride
RxNorm normalized name: CHLORIDE
DrugBank: Pudexacianinium (DB19161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection
Trial: NCT00008489
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04654351
Drug: TAK-667
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-667 single SC administration
Trial: NCT06234397
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
Trial: NCT04589208
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
Trial: NCT04965493
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04965493
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT04965493
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV)
Trial: NCT06298032
Drug: Olamkicept Part A
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg
Trial: NCT06068153
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
Trial: NCT06068153
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
Trial: NCT04976036
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
Trial: NCT04913831
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
Trial: NCT06508749
Drug: ART Regimen prior to enrolling in Step 1a
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.
Trial: NCT06508749
Drug: ART Regimen prior to enrolling in Step 1b
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.
Trial: NCT06494072
Drug: Ampicillin for Injection
RxNorm normalized name: Ampicillin for Injection
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Trial: NCT04834856
Drug: ensovibep
RxNorm normalized name: Ensovibep
DrugBank: Ensovibep (DB19078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
Trial: NCT00729768
Drug: basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 intravenous doses
Trial: NCT00729768
Drug: efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous repeating dose
Trial: NCT00729768
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral repeating dose
Trial: NCT00729768
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT06494072
Drug: Ceftriaxone for Injection
RxNorm normalized name: Ceftriaxone for Injection
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Trial: NCT06494072
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Trial: NCT06494072
Drug: Ampicillin / Sulbactam Injection
RxNorm normalized name: ampicillin / sulbactam Injection
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Trial: NCT06494072
Drug: Amoxicillin-clavulanate
RxNorm normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Trial: NCT06494072
Drug: Cefprozil
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Trial: NCT06494072
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Trial: NCT06515184
Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
RxNorm normalized name: Bio-Kool
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.
Trial: NCT06515184
Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
RxNorm normalized name: Bio-Kool
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.
Trial: NCT04727853
Drug: irinotecan liposome injection
RxNorm normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: irinotecan liposome injection
Trial: NCT05008224
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
Trial: NCT05008224
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
Trial: NCT05008224
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Trial: NCT05008224
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Trial: NCT05008224
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Trial: NCT05008224
Drug: Procarbazine
RxNorm normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Trial: NCT05008224
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Trial: NCT05363462
Drug: Vancomycin 1000 MG
RxNorm normalized name: vancomycin 1000 MG
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
Trial: NCT06648096
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
Trial: NCT05885932
Drug: Aspirin and clopidogrel or ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
Trial: NCT06170710
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W
Trial: NCT05910931
Drug: ICG angiography
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~* A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~* A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used.
Trial: NCT05324982
Drug: Oral CBG Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBG cannabis oil will be orally self-administered by study participants.
Trial: NCT06698211
Drug: Posaconazole tablet
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined. Once patients developed GI GVHD, first line therapy and second line treatment will be reviewed according to the condition, besides which the Posaconazole plasma concentration would be detected again on the first, third and fifth day after onset of GI GVHD symptoms to monitor the impact of GI GVHD on the Posaconazole plasma concentration.
Trial: NCT06696664
Drug: PEG-IFN-α
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks
Trial: NCT00001032
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001032
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06319456
Drug: Lisaftoclax (APG-2575)
RxNorm normalized name: APGA
DrugBank: Lisaftoclax (DB18054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, oral administration, every 28 days for a dosing cycle.
Trial: NCT06319456
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BID, oral administration, every 28 days for a dosing cycle.
Trial: NCT06319456
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Trial: NCT06319456
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Trial: NCT06319456
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Trial: NCT05283746
Drug: Epetraborole
RxNorm normalized name: Epetraborole
DrugBank: Epetraborole (DB11744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epetraborole hydrochloride 250 mg tablets for oral administration
Trial: NCT05257031
Drug: SmofKabiven extra Nitrogen
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
Trial: NCT06248606
Drug: Adagrasib
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adagrasib 600mg orally
Trial: NCT05148767
Drug: Neoadjuvant chemoradiotherapy based on irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）.
Trial: NCT04483076
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.
Trial: NCT05020288
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
Trial: NCT05110664
Drug: PYY (3-36) Peptide
RxNorm normalized name: Pyy (3-36) peptide
DrugBank: Peptide YY (3-36) (DB05004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral PYY3-36 solution
Trial: NCT04860700
Drug: anlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT05604898
Drug: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 608 will be administered subcutaneously.
Trial: NCT05604898
Drug: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 608 will be provided at pre-specified time intervals.
Trial: NCT04947423
Drug: DPI-386 Nasal Gel
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Trial: NCT05725200
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
Trial: NCT05589974
Drug: Verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chronic CSC are receiving one treatment before the observation period.